The global viscosupplementation market is projected to reach USD 3.07 billion by 2028, growing at a CAGR of 9.9%. Increasing cases of osteoarthritis, up surging elderly populace and demand for minimally invasive treatments is driving the global viscosupplementation market.
Adroit Market Research report on global viscosupplementation market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global viscosupplementation market have been studied in detail.
Osteoarthritis (OA) is the most prevalent joint disease and is associated with pain and disability. It is a major cause of morbidity and restricted mobility in individuals over 40 years of age. Viscosupplementation (VS) is the intra-articular injection of exogenous hyaluronic acid for the treatment of osteoarthritis. Hyaluronic acid exists in several organisms, and when it is not bound to other molecules, it binds to water and becomes gelatinous. Intra-articular injection of hyaluronic acid helps improving the rheological properties of the synovial fluid, serving both as a lubricant and as a shock absorber; analgesia; and improvement of joint homeostasis by decreasing inflammation and positively stimulating chondrocytes.
The global viscosupplementation market is categorized based on product and end use. On the basis of end use, the market is segmented into hospitals and orthopedic clinics/ambulatory surgical centers. The ambulatory surgical centers dominated the market in 2019 due to shorter length of stay resulting in decreased accommodation costs.
Asia Pacific dominated the market for viscosupplementation in 2019, while Europe is anticipated to grow at a highest CAGR owing to increasing reimbursement policies. Key players of the global viscosupplementation market include Sanofi, Seikagaku Corporation, Zimmer Holdings Inc., Ferring B.V., Bioventus, Lifecore Biomedical, LLC, Anika Therapeutics, Inc., LG Life Sciences Ltd. among others.
Key segments of the global viscosupplementation market
Product Overview, 2018-2028 (USD Billion)
- Single Injection
- Three Injection
- Five Injection
End Use Overview, 2018-2028 (USD Billion)
- Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa